New CMO at VectorY

VectorY Therapeutics NV, a developer of vectorised antibodies for neurodegenerative diseases, has appointed Olga Uspenskaya-Cadoz as chief medical officer. The Netherlands-based biotech company plans to submit by the end of 2025 an investigational new drug (IND) application with the US Food and Drug Administration for its lead candidate VTx-002 in sporadic amyotrophic lateral sclerosis (ALS), and to enter clinical development in 2026. Dr Uspenskaya-Cadoz joins VectorY from Eli Lilly, where she was vice president, medical, gene therapy. Previously she was vice president of clinical development at Prevail Therapeutics. She has contributed to large-scale clinical trials in Alzheimer’s disease and ALS and conducted studies on neurochemical biomarkers and neuroimaging in Alzheimer’s disease. Dr Uspenskaya-Cadoz holds an MD and PhD in neurosciences from First Moscow State Medical University, Russia.

VectorY announced the appointment on 1 April 2025.